BTMD Stock Price, Biote Corp Quote, Chart

Market Summary

USD5.78+0.13

Market Closed

2.30%

BTMD Stock Price

View Fullscreen

BTMD RSI Chart

BTMD Valuation

Market Cap

148.6M

Price/Earnings (Trailing)

-18.64

Price/Sales (Trailing)

0.8

EV/EBITDA

13.46

Price/Free Cashflow

5.6

BTMD Price/Sales (Trailing)

BTMD Profitability

Operating Margin

73.66%

EBT Margin

-0.07%

Return on Equity

21.81%

Return on Assets

-5.13%

Free Cashflow Yield

17.85%

BTMD Fundamentals

BTMD Revenue

Revenue (TTM)

185.4M

Rev. Growth (Yr)

2.74%

Rev. Growth (Qtr)

0.32%

BTMD Earnings

Earnings (TTM)

-8.0M

Earnings Growth (Yr)

1.1K%

Earnings Growth (Qtr)

152.62%

Breaking Down BTMD Revenue

Last 7 days

3.6%

Last 30 days

0.2%

Last 90 days

46.7%

How does BTMD drawdown profile look like?

BTMD Financial Health

Current Ratio

5.51

Debt/Equity

-2.92

Debt/Cashflow

0.25

BTMD Investor Care

Shares Dilution (1Y)

219.00%

Diluted EPS (TTM)

0.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	172.7M	180.6M	184.1M	185.4M
2022	145.0M	151.6M	158.0M	165.0M
2021	122.3M	128.0M	133.7M	139.4M
2020	0	0	0	116.6M
2019	0	0	0	110.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biote Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 05, 2023	conlon mary elizabeth	sold	-40,573	6.5021	-6,240	general counsel
Jun 30, 2023	conlon mary elizabeth	acquired	-	-	24,231	general counsel
Jun 30, 2023	cone stephen mark	acquired	-	-	6,058	-
Jun 30, 2023	jacoby dana lynn	acquired	-	-	6,058	-
Jun 09, 2023	roystone capital management lp	acquired	-	-	99,372	-
Apr 04, 2023	conlon mary elizabeth	sold	-64,382	5.9246	-10,867	general counsel
Mar 31, 2023	conlon mary elizabeth	acquired	-	-	39,375	general counsel
Mar 31, 2023	cone stephen mark	acquired	-	-	9,844	-
Mar 31, 2023	jacoby dana lynn	acquired	-	-	9,844	-
Feb 07, 2023	roystone capital management lp	bought	1,218,750	3.25	375,000	-

Which funds bought or sold BTMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	2,598	2,598	-%
Apr 26, 2024	ZWJ INVESTMENT COUNSEL INC	unchanged	-	10,962	73,927	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-8.16	24,976	344,049	-%
Apr 25, 2024	Mesirow Financial Investment Management, Inc.	sold off	-100	-232,743	-	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	595	2,900	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-69.97	-5,000	3,000	-%
Apr 18, 2024	WASATCH ADVISORS LP	reduced	-37.56	-1,414,340	3,885,190	0.02%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	238	238	-%

Are Funds Buying or Selling BTMD?

Are funds buying BTMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BTMD

No. of Funds

Unveiling Biote Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	roystone capital management lp	6.9%	2,349,372	SC 13G/A
Feb 14, 2024	roystone capital management lp	9.0%	3,070,938	SC 13G/A
Feb 13, 2024	boston partners	2.45%	831,841	SC 13G/A
Feb 13, 2024	bandera partners llc	5.4%	1,832,732	SC 13G/A
Feb 12, 2024	lmr partners llp	0%	0	SC 13G/A
Oct 12, 2022	lmr partners llp	4.2%	397,884	SC 13G

Recent SEC filings of Biote Corp

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 09, 2024	424B3	Prospectus Filed
Apr 09, 2024	424B3	Prospectus Filed
Apr 03, 2024	S-8	Employee Benefits Plan
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Biote Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	454.8B	371.6B	7.68%	0.79%	20.32	1.22	14.64%	11.24%
CI	97.8B	206.0B	-5.16%	39.98%	25.38	0.47	12.55%	-43.95%
HCA	80.9B	66.7B	-6.23%	11.01%	14.79	1.21	9.59%	-4.59%
CVS	69.3B	360.9B	-25.25%	-21.26%	9.46	0.19	9.07%	78.49%
CNC	39.7B	155.5B	2.59%	8.16%	14.5	0.26	6.34%	84.42%
DVA	12.5B	12.3B	5.32%	61.32%	15.29	1.01	5.77%	58.74%
UHS	11.8B	14.3B	-1.51%	19.13%	16.4	0.82	6.59%	6.24%
MID-CAP
CHE	8.5B	2.3B	-12.14%	1.66%	29.89	3.69	5.96%	18.29%
ACHC	6.2B	3.0B	-11.92%	-1.82%	-547.75	2.07	10.92%	-104.06%
AMN	2.3B	3.8B	3.30%	-28.74%	10.81	0.6	-27.73%	-52.50%
AMEH	2.1B	1.4B	-11.91%	5.74%	33.82	1.48	21.19%	34.42%
SMALL-CAP
ADUS	1.6B	1.1B	-3.20%	17.84%	25.54	1.51	11.31%	35.83%
BKD	1.4B	3.0B	10.43%	83.67%	-7.21	0.45	6.74%	20.73%
BEAT	57.9M	-	5.26%	-4.76%	-3.96	-	-	-12.94%
AMS	18.5M	21.3M	-	6.55%	34.8	0.87	8.00%	-62.25%

Biote Corp News

Latest updates

Biote Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Revenue	0.3%	45,703	45,557	49,257	44,843	44,485	41,970	41,359	37,143	37,536	35,567	34,750	-	-	-
Cost Of Revenue	-	-	-	-	-	-	-	-	12,277	-	-	-	11,361	-	-
S&GA Expenses	10.1%	26,190	23,791	25,760	23,085	21,758	20,818	113,425	15,103	15,953	12,311	11,327	9,463	-	-
EBITDA Margin	-17.0%	0.07*	0.08*	-0.05*	-0.12*	0.05*	-0.01*	0.04*	0.25*	0.26*	0.25*	0.26*	0.27*	0.28*	0.22*
Interest Expenses	0.5%	2,454	2,441	2,351	2,230	1,938	1,506	678	304	313	355	302	492	-	-
Income Taxes	-170.7%	-2,757	3,900	922	630	454	200	-346	64.00	77.00	67.00	78.00	64.00	-	-
Earnings Before Taxes	-60.3%	9,334	23,516	-12,173	-20,800	13,245	728	-21,675	9,414	5,557	8,604	9,839	8,905	-	-
EBT Margin	-103.2%	0.00*	0.02*	-0.11*	-0.17*	0.01*	-0.04*	0.01*	0.23*	0.24*	0.22*	0.23*	0.24*	0.25*	0.19*
Net Income	152.6%	19,023	7,530	-13,095	-21,430	1,622	15.00	-2,606	9,350	5,480	8,537	9,761	8,841	-	-
Net Income Margin	68.8%	-0.04*	-0.14*	-0.18*	-0.13*	-0.01*	0.04*	0.08*	0.23*	0.23*	0.20*	0.15*	0.24*	0.25*	0.19*
Free Cashflow	2545.0%	7,115	-291	6,770	12,930	6,046	6,393	-28,636	6,707	9,406	6,569	8,482	7,815	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	3.7%	155	150	139	119	112	110	115	59.00	54.00	318	318	319	33.00
Current Assets	3.9%	122	118	112	107	101	101	106	52.00	47.00	1.00	1.00	2.00	28.00
Cash Equivalents	35.7%	89.00	66.00	68.00	88.00	79.00	77.00	83.00	28.00	27.00	0.00	0.00	21.00	17.00
Inventory	56.2%	17.00	11.00	7.00	10.00	11.00	10.00	10.00	9.00	10.00	-	-	-	4.00
Net PPE	-10.0%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	-	-	-	2.00
Liabilities	-4.6%	192	201	212	203	170	180	187	49.00	50.00	22.00	25.00	39.00	50.00
Current Liabilities	-11.4%	22.00	25.00	22.00	20.00	19.00	22.00	33.00	17.00	17.00	0.00	0.00	0.00	12.00
Long Term Debt	-1.3%	107	108	109	111	112	113	115	-	32.00	-	-	-	37.00
LT Debt, Current	0%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	-	5.00	-	-	-	5.00
LT Debt, Non Current	-1.3%	107	108	109	111	112	113	115	-	32.00	-	-	-	37.00
Shareholder's Equity	-Infinity%	-36.55	-	-	-	-58.27	-	-	11.00	4.00	-	5.00	5.00	0.00
Retained Earnings	27.5%	-29.39	-40.52	-46.39	-48.53	-44.46	-48.12	-49.14	11.00	4.00	-21.45	-24.45	-37.69	-17.05
Additional Paid-In Capital	-	-	-	-	-	-	-	-	0.00	-	-	-	9.00	0.00
Shares Outstanding	-15.2%	26.00	30.00	21.00	18.00	8.00	8.00	8.00	-	-	-	-	-	-
Minority Interest	33.4%	-7.15	-10.74	-26.83	-35.27	-13.81	-22.73	-22.17	-	-	-	-	-	-
Float	-	-	-	169	-	-	-	8.00	-	-	-	307	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	4247.5%	6,956	160	6,775	12,992	6,051	6,393	-28,570	6,969	10,080	6,322	9,361	7,957	-	-	-
Share Based Compensation	-11.0%	1,997	2,243	2,647	2,170	2,164	746	79,270	-	-	-	-	-	-	-	-
Cashflow From Investing	4024.8%	18,996	-484	-20,845	-380	-311	-387	-658	-482	-1,047	-1,329	-946	-485	-	-	-
Cashflow From Financing	1.4%	-2,525	-2,562	-5,058	-4,235	-3,976	-11,262	84,260	-5,562	-5,190	-4,686	-6,875	-3,592	1.00	250*	-
Dividend Payments	10.6%	1,106	1,000	3,495	3,093	2,276	1,903	5,972	2,735	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BTMD Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenue	$ 185,360	$ 164,957
Cost of revenue
Cost of revenue	57,877	54,575
Selling, general, and administrative	98,826	171,104
Income (loss) from operations	28,657	(60,722)
Other income (expense) net :
Interest expense, net	(6,363)	(4,047)
Gain (loss) from change in fair value of warrant liability	(13,411)	5,127
Gain (loss) from change in fair value of earnout liability	(8,990)	61,770
Loss from extinguishment of debt		(445)
Other income (expense)	(16)	29
Total other income (expense), net	(28,780)	62,434
Income (loss) before provision for income taxes	(123)	1,712
Income tax expense	2,682	388
Net income (loss)	(2,805)	1,324
Less: Net income (loss) attributable to noncontrolling interest	(6,121)	2,293
Net income (loss) attributable to biote Corp. stockholders	3,316	(969)
Other comprehensive income (loss):
Foreign currency translation adjustments	8	(1)
Other comprehensive income (loss)	8	(1)
Comprehensive income (loss)	$ (2,797)	$ 1,323
Net income (loss) per common share
Basic	$ 0.13	$ (0.12)
Diluted	$ 0.13	$ (0.12)
Weighted average common shares outstanding
Basic	25,709,343	8,059,371
Diluted	25,709,343	8,059,371
Product Revenue
Revenue
Total revenue	$ 182,573	$ 163,133
Cost of revenue
Cost of revenue	54,246	51,990
Service Revenue
Revenue
Total revenue	2,787	1,824
Cost of revenue
Cost of revenue	$ 3,631	$ 2,585

BTMD Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 89,002	$ 79,231
Accounts receivable, net	6,809	6,948
Inventory, net	17,307	11,183
Other current assets	9,225	3,816
Total current assets	122,343	101,178
Property and equipment, net	1,218	1,504
Capitalized software, net	4,973	5,073
Operating lease right-of-use assets	1,877	2,052
Deferred tax asset	24,884	1,838
Total assets	155,295	111,645
Current liabilities
Accounts payable	4,155	4,112
Accrued expenses	8,497	6,274
Term loan, current	6,250	6,250
Deferred revenue, current	3,002	1,965
Operating lease liabilities, current	311	165
Total current liabilities	22,215	18,766
Term loan, net of current portion	106,630	112,086
Deferred revenue, net of current portion	1,322	926
Operating lease liabilities, net of current portion	1,680	1,927
TRA liability	18,894
Warrant liability		4,104
Earnout liability	41,100	32,110
Total liabilities	191,841	169,919
Commitments and contingencies (See Note 18)
Stockholders' Deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022
Additional paid-in capital	0	0
Accumulated deficit	(29,391)	(44,460)
Accumulated other comprehensive loss	(12)	(5)
biote Corp.'s stockholders' deficit	(29,397)	(44,459)
Noncontrolling interest	(7,149)	(13,815)
Total stockholders' deficit	(36,546)	(58,274)
Total liabilities and stockholders' deficit	155,295	111,645
Class A Common Stock
Stockholders' Deficit
Common stock value	3	1
Class V Common Stock
Stockholders' Deficit
Common stock value	$ 3	$ 5

About Biote Corp

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irvine, Texas.

CEO	Ms. Teresa S. Weber
WEBSITE	https://biote.com
INDUSTRY	Healthcare Plans
EMPLOYEES	186

Biote Corp Frequently Asked Questions

What is the ticker symbol for Biote Corp? What does BTMD stand for in stocks?

BTMD is the stock ticker symbol of Biote Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biote Corp (BTMD)?

As of Thu May 02 2024, market cap of Biote Corp is 148.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTMD stock?

You can check BTMD's fair value in chart for subscribers.

What is the fair value of BTMD stock?

You can check BTMD's fair value in chart for subscribers. The fair value of Biote Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biote Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biote Corp a good stock to buy?

The fair value guage provides a quick view whether BTMD is over valued or under valued. Whether Biote Corp is cheap or expensive depends on the assumptions which impact Biote Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTMD.

What is Biote Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, BTMD's PE ratio (Price to Earnings) is -18.64 and Price to Sales (PS) ratio is 0.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTMD PE ratio will change depending on the future growth rate expectations of investors.